Articles with keyword therapy

• The history of targeted therapy

  I.A. Gerk

  targeted therapy

• Resistance to targeted therapy

  F.V. Moiseenko, V.M. Moiseyenko

  malignant tumors, lung cancer, molecular markers, targeted therapy, resistance.

• Epigenetics: perspectives of targeted therapy

  N.M. Volkov

  malignant tumors, epigenetics, therapy, carcinogenesis, gene expression.

• 2015 main events in drug therapy

  F.V. Moiseenko

  immunotherapy, program cell death protein inhibitors, targeted therapy, cancer drug therapy

• SYSTEMIC THERAPY FOR ADVANCED KIDNEY CANCER

  I.V. Timofeev

  metastatic renal cell carcinoma, systemic therapy, nivolumab, ipilimumab, avelumab, axitinib, pembrolizumab, PD-L1 expression, cytoreductive nephrectomy.

• 2016: new directions in radiation therapy

  N.V. Dengina, T.V. Mitin, A.O. Likhacheva

  radiotherapy, breast cancer, prostate cancer, targeted therapy, abscopal effect, hepatocellular carcinoma, intrahepatic cholangiocarcinoma

• CRITICAL VIEW OF EFFICACY ANTIANGIOGENIC THERAPY IN ONCOLOGY

  M.Yu. Fedyanin, A.A. Tryakin, I.A. Pokataev

  antiangiogenic therapy, bevacizumab, resistance, biomarkers.

• MATHEMATICAL MODELING AND OPTIMIZATION OF TARGETED TUMOR THERAPY

  A.A. Bogdanov

  cancer, targeted therapy, mathematical modeling, forecasting, new regimens of therapy.

• RE-IRRADIATION THERAPY FOR RECURRENT BRAIN TUMORS

  O.I. Shcherbenko, O.S. Regentova

  brain tumors, relapses, radiation therapy, chemotherapy, medulloblastoma, ependymoma, glioma, brain stem tumor, radiation injuries.

• Individualization of adjuvant therapy: who can I refuse?

  E.V. Karabina

  adjuvant therapy, benefits and harms of adjuvant therapy, risk stratification of adjuvant therapy, circulating tumor DNA, gene expression profiling, simulation modeling

• Targeted therapy: twenty years of success and failures

  S.A. Tyulyandin

  targeted therapy, oncology, cancer, melanoma, tumor evolution.

• Possibilities of cytostatics, hormonal and targeted therapy for operable tumors

  N.V. Levchenko

  adjuvant therapy, targeted therapy, combination hormonal therapy, breast cancer, lung cancer

• Possibilities of intraluminal photodynamic therapy in oncology (review)

  A.E. Akkalaeva, V.V. Klimenko, A.A. Avanesyan, V.V. Egorenkov, A.A. Bogdanov, V.M. Moiseyenko

  tumor stenosis, photodynamic therapy, endoscopy, early cancer, photosensitizers.

• Oncologic Surgery in the era of drug therapy

  V.V. Egorenkov

  immunotherapy, adoptive therapy, T-lymphocyte, tumor-infiltrating lymphocytes, melanoma, malignant tumors

• Neoadjuvant endocrine therapy for breast cancer: state of the art

  А.А. Zavialov, A.I. Tyryshkin, S.E. Varlamova.

  breast cancer, neoadjuvant treatment, hormone therapy.

• FUTURE OF SYSTEMIC THERAPY IN ONCOUROLOGY: TARGETED AND IMMUNOTHERAPY

  F.V. Moiseenko

  immunotherapy, targeted therapy, checkpoint inhibitors, urothelial cancer, renal cell cancer.

• Rationale for systemic therapy administration in clinically localised tumors

  N.M. Volkov

  localized tumors, systemic therapy, micrometastases, disseminated tumor cells, survival.

• The effect of auxiliary drugs on photodynamic cytolysis in photodynamic therapy

  Е.В. Miroshnikova, L.V. Galebskaya, V.A. Dadali, Y.V. Dadali, B.I. Miroshnikov

  photodynamic therapy, antioxidant, prooxidant, photoinduced hemolysis, radachlorin, singlet oxygen, mexidol

• Hormone replacement therapy in patients with a history of cancer

  N.E. Levchenko, E.A. Efremov, E.V. Kasatonova, Yu.S. Sidorenko, Y.I. Melnik, A.V. Koryakin

  cancer survivor, estrogen replacement, testosterone replacement, HRT, hormone replacement therapy, MHT, menopausal hormone therapy, recurrence risk.

• MOLECULAR-ORIENTED AND PRECISION CANCER THERAPY – THE PRESENT AND FUTURE ASPECTS

  D.B. Korman

  cancer, molecular-oriented drugs, precision therapy, sequencing DNA, tumor-associated mutations, tumor-type agnostic therapy.

• 20 YEARS OF TARGETING THERAPY OF SOLID TUMORS. SUCCESSES AND FAILURES

  A.A. Tryakin, M.Yu. Fedyanin, I.A. Pokataev

  targeted therapy, precision medicine, tyrosine kinase inhibitor, biomarker, oncology; review.

• Efficacy of neoadjuvant endocrine therapy in HR-positive/HER2-negative breast cancer: A review

  N.K. Abduloeva, V.M. Moiseenko, F.V. Moiseenko, O.A. Skripko, M.V. Scriabin, R.A. Ryandjina

  Neoadjuvant endocrine therapy, neoadjuvant chemotherapy.

• Direct photogeneration of singlet oxygen in biological medium for cancer therapy

  A.A. Bogdanov, V.V. Klimenko, An.A. Bogdanov, N.A. Verlov, V.M. Moiseyenko

  single oxygen, direct photogeneration, reactive oxygen species, cancer therapy, photobiomodulation.

• Long-term outcomes of neoadjuvant endocrine therapy versus chemotherapy in luminal HER2-breast cancer

  N.K. Abduloeva, V.M. Moiseenko, F.V. Moiseenko. O.A. Skripko, M.V. Scriabin, R.A. Ryanjina

  neoadjuvant, endocrine therapy, hormone therapy, locoregional recurrence, pathologic response, overall recurrence.

• Neuroradiology: evaluation of effectiveness of surgery and the combined therapy of gliomas

  T.N.Trofimova

  MRI, PET, CT, glioma, chemo-radiation therapy, perfusion, spectroscopy

• Palliative radiation therapy – is there a place for this method in modern practical oncology

  T.M. Sharabura, T.N. Bochkareva

  palliative radiation therapy, stereotactic ablative radiotherapy, oligometastatic disease, immunotherapy

• EVOLUTION OF DRUG THERAPY FOR LUNG CANCER WITH EGFR INHIBITORS: NEW ASPECTS

  M.L. Stepanova, L.V. Khalicova, A.S. Zhabina, F.V. Moiseenko

  non-small cell lung cancer, epidermal growth factor receptor, targeted therapy, osimertinib.

• The most important results of clinical trials for breast cancer systemic therapy in 2021

  S.A. Tjulandin, М.В. Stenina, М.А. Frolova

  breast cancer, immunotherapy, endocrine therapy, chemotherapy, gene expression assay, BRCA1/2-associated breast cancer.

• Possibilities of systemic therapy in elderly, frail, patients with comorbidities and poor performance status

  I.A. Gerk

  palliative care, elderly patients, geriatric assessment, frail, comorbidity, poor performance status, metronomic therapy

• Clinical experience of afatinib application In non-cell lung cancer of lung. Ii line of therapy

  L.M. Kogoniya, E.V. Markarova, G.A. Stashuk, V.E. Shikina

  lung cancer, adenocarcinoma, non-small cell lung cancer, EGFR mutation, chemotherapy, targeted therapy, efficacy, elderly, side effects

• Dynamics of pathological factors after «test» course of preoperative endocrine therapy in menopausal patients with earlyer positive breast cancer and its effect on survival

  M.A. Frolova, M.B.Stenina, Y.I. Kochetkova, A.V. Petrovsky, O.V. Krohina, Y.V. Vishnevskaya, S.A. Tyulyandin

  ER positive breast cancer, preoperative endocrine therapy, Ki67.

• PROMISING METHODS FOR THE TREATMENT OF METASTATIC BREAST CANCER

  A.S. Zhabina

  metastatic breast cancer, high-dose chemotherapy, metronome therapy, vaccine therapy, adoptive therapy.

• External radiotherapy – hystory, advantages, perspectives

  G.M. Zharinov, N.Ju. Neklasova

  external radiotherapy, balance-therapy

• What is the role of radiotherapy for management of soft tissue and bone sarconas?

  T.M. Sharabura

  bone and soft tissue sarcomas, radiotherapy, stereotactic radiation therapy, hadron therapy.

• Prognostic significance of longitudinal evaluation on egfr mutant ctdna during tki treatment in nsclc

  F.V. Moiseenko, N.M. Volkov, A.S. Zhabina, M.L. Stepanova, N.A. Rjsev, V.V. Klimenko, A.V. Myslik, E.V. Artemieva, N.H. Abduloeva, V.V. Egorenkov, V.M. Moiseyenko

  mutations, EGFR, tumor, ctDNA, therapy.

• Optimal dosage and duration of treatment for patients with malignant tumors. are approved guidelines always correct?

  M.A. Krasavina, V.M. Moiseenko

  medical oncology, targeted therapy, immune therapy, pharmaceutical industry, dosage, regimens.

• CHANGES IN NEO- AND ADJUVANT TREATMENT OF BREAST CANCER IN THE LAST 5 YEARS

  M.B. Stenina, M.A. Frolova, D.Z. Kupchan, S.A. Tjulandin

  early breast cancer, neo-adjuvant therapy, adjuvant therapy, radiotherapy, chemotherapy, hormonotherapy, anti-HER2 therapy, ovarian suppression.

• What has changed in clinical oncology practice In 2019?

  M.Y. Fedyanin

  cancer, chemotherapy, immunotherapy, targeted therapy.

• Microbiome and its role in oncology

  F.V. Moiseenko, S.V. Ugai, N.M. Volkov

  drug therapy, cancer, microbiome, immunotherapy.

• Cancer evolution as a new target of treatment paradigm

  V.A. Chubenko

  tumor evolution, microenvironment, therapy strategy.

• Microbiome as a therapeutic target

  F.V. Moiseenko

  drug therapy, cancer, microbiome, immunotherapy.

• The role of androgen receptor in breast cancer. Reviewwork

  Y.I. Kochetkova, M.A. Frolova, M.B. Stenina

  breast cancer, androgen receptors, endocrine therapy.

• Prospects for the use of small interfering RNAs as inhibitors of immune checkpoints for immunotherapy in oncology

  A.A. Bogdanov, V.V. Vysochinskaya, A.A. Kornev, A.K. Emelyanov, An.A. Bogdanov, V.M. Moiseyenko

  immunotherapy, adaptive cell therapy, RNA interference, targeted therapy, immune checkpoint inhibitors.

• Role of supportive care as an element of antitumor treatment

  М.М. Kramchaninov

  cancer, solid tumors, antitumor drugs, supportive therapy

• The role of stereotaxic body radiotherapy (sbrt) in the treatment of patients with distant metastases

  N.V. Dengina

  oligometastases, radiation therapy, SBRT, abscopal effect, immunotherapy

• Colorect al molecular subtypes – progress or deadlock ?

  M.Yu. Fedyanin, E.O. Ignatova, А.А. Tryakin

  colorectal cancer, molecular subtypes, immunotherapy, targeted therapy.

• 2016: advances in medical oncology

  V.A. Chubenko

  immunotherapy, target therapy, overall survival, treatment guidelines

• PREVENTION OF VIRUS-ASSOCIATED CANCERS

  А.A. Barchuk

  prevention, vaccination, virus-associated cancers, antiviral therapy, screening.

• MEDICAL TREATMENT OF TUMORS: WHAT NEED TO KNOW A PRAC TICAL ONCOLOGIST

  V.A. Chubenko

  chemotherapy, immunotherapy, target therapy, overall survival, treatment guidelines.

• Combinations of immunotherapy and other drugs

  V.A. Chubenko

  Target therapy, chemotherapy, check-point inhibitors, overall survival.

• Tumor-infiltrating lymphocytes – from theory to real practice

  N.M. Volkov

  immunotherapy, adoptive therapy, T-lymphocyte, tumor-infiltrating lymphocytes, melanoma, malignant tumors.

• A history of cancer immunotherapy

  V.M. Moiseyenko, N.M. Volkov

  anticancer immunity, cancer immunotherapy, history, vaccines, cytokines, adoptive therapy, antibody, immune check-point inhibitor

• DUCTAL CANCER OF PANCREATIC HEAD NEOADJUVANT TREATMENT: CLOSE AND END RESULTS

  R.I. Rasulov, M.V. Zemko, I.V. Ushakova, G.I. Songolov

  pancreatic head cancer, neoadjuvant treatment, gastroduodenal artery chemoembolization, radiation therapy.

• Stereotactic radiotherapy vs. surgery in the treatment of colorectal cancer liver oligometastases

  A.N. Moskalenko, V.K. Lyadov, M.V. Chernykh, I.V. Sagaydak, D.G. Ichshanov, M.R. Garipov, V.N. Galkin.

  Stereotactic radiation therapy, colorectal cancer, oligometastatic liver disease, hepatic resection.

• Modern approa hes to the treatment of primary multiple unilateral synchronous lung tumors (literature review)

  I.V. Mosin, S.M. Nuraliev, A.G. Pavlov, V.M. Moiseenko

  Lung cancer, primary multiple synchronous and metachronous lung tumors, classification, diagnosis, staging, stereotactic radiation therapy, targeted therapy, immunotherapy, anatomical segmentectomy, lobectomy, bronchoplastic surgery.

• ACCELERATED PROTONS IN THE TREATMENT OF CNS TUMORS IN CHILDREN: A REVIEW OF THE LITERATURE

  O.I. Shcherbenko

  сhildren, CNS tumors, radiation therapy, accelerated protons, photon radiation, complications, cost of treatment.

• Advances in fundamental oncology: Year 2019 update

  E.N. Imyanitov

  oncology, genome, resistance to therapy, genomic profiling of neoplasms, clinical trials.

• BIOLOGY OF BREAST CANCER

  E.N. Imyanitov

  pathogenesis of breast cancer, metastasis of breast cancer, breast cancer therapy, hereditary breast cancer.

• Cell-based anticancer immunotherapy methods

  N.M. Volkov

  сell-based immunotherapy, adoptive therapy, dendritic cell, vaccine, T-lymphocyte, natural killer, cancer

• EVOLUTION OF TYROSINE KINASE RESISTANCE IN EGFR MUTATED NON-SMALL CELL LUNG CANCER

  F.V. Moiseenko

  non-small cell lung cancer, epidermal growth factor receptor, targeted therapy, resistance.

• Immunotherapy: Neoadjuvant and/or adjuvant? Literature review

  N.A. Falaleeva, E.A. Bykova, L.Yu. Grivtsova, A.S. Belokhvostova, A.А. Danilenko, I.S. Pimonova, P.V. Shegai, S.A. Ivanov, A.D. Kaprin

  Neoadjuvant immunotherapy, immune checkpoint inhibitors, breast cancer, colorectal cancer, non-small cell lung cancer, nonspecific immunotropic therapy.

• Acid-base balance in the regulation of tumor growth: value for the clinicians

  A.A. Bogdanov, An.A. Bogdanov

  tumor acidosis, resistance to therapy, immune response, pH correction methods, clinical pH measurement.

• Multifactorial analysis of the dependence of prescribed diagnostic test systems and purchased targeted drugs on the example of lung adenocarcinoma in St.P.

  D.D. Zelikova, D.S. Yurochkin, S.E. Erdni-Garyaev, A.A. Leshkevich, Z.M. Golant, D.A. Chagin, N.M. Volkov, F.V. Moiseenko, V.M. Moiseenko

  Non-small cell lung cancer, EGFR mutation, drug provision, targeted therapy, molecular genetic test systems.

• Prevention of smoking-associated forms of cancer: harm reduction concept

  D.G. Zaridze, A.F. Mukeria

  trends, smoking prevalence, mortality, lung cancer, nicotine replacement therapy, electronic nicotine delivery systems, harm reduction.

• Interventional radiology in the treatment of oncologic emergencies

  P.V. Balakhnin

  emergencies in oncology, interventional radiology, stents, percutaneous drainage, embolization, local therapy, central venous catheters, inferior vena cava filter

• Efficacy of immune checkpoints inhibitors in the treatment of solid tumors

  A.A. Rumyantsev, S.A. Tjulandin

  drug therapy, immunotherapy, CTLA-4, PD-1, PD-L1, check-points, programmed cell death protein, nivolumab, pembrolizumab, ipilimumab, atezolizumab, biomarkers, efficacy

• Assessment of the reliability of the criteria for the consistency of radioiodablation

  V.A. Solodkiy, D.K. Fomin, O.A. Borisova, Y.A. Blanter

  differentiated thyroid cancer, thyroid carcinoma, thyroid remnant, radioiodine ablation, 99mTc-pertechnetate scintigraphy, post therapeutic scintigraphy whole body with 131I, thyroglobulin, TSH, thyroid-stimulating hormone, sodium iodine symporter, radioiodine therapy, thyrotropin alpha, dosimetry